Clinical Trials Directory

Trials / Completed

CompletedNCT02299687

Influence of CYP2C19 Polymorphism on PK/PD of Omeprazole

A Clinical Trial to Investigate the Influence of CYP2C19 Polymorphism on Pharmacokinetic/Pharmacodynamic Characteristics of Omeprazole in Healthy Korean Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
24 (actual)
Sponsor
Seoul National University Hospital · Academic / Other
Sex
All
Age
20 Years – 45 Years
Healthy volunteers
Accepted

Summary

A clinical trial to investigate the influence of CYP2C19 polymorphism on pharmacokinetic/pharmacodynamic characteristics of omeprazole in healthy Korean volunteers

Conditions

Interventions

TypeNameDescription
DRUGOmeprazole

Timeline

Start date
2014-09-01
Primary completion
2014-12-01
First posted
2014-11-24
Last updated
2015-01-01

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT02299687. Inclusion in this directory is not an endorsement.

Influence of CYP2C19 Polymorphism on PK/PD of Omeprazole (NCT02299687) · Clinical Trials Directory